[1] Islam MM, Nasrin T, Walther BA, et al.Prediction of sepsis patients using machine learning approach: a meta-analysis[J]. Comput Methods Programs Biomedi, 2019, 170: 1-9. [2] Cheng Z, Abrams ST, Toh J, et al.The critical roles and mechanisms of immune cell death in sepsis[J]. Front Immunol, 2020, 11: 1918. [3] Schrijver IT, Théroude C, Roger T.Myeloid-derived suppressor cells in sepsis[J]. Front Immunol, 2019, 10: 327. [4] Chen X, Wei Q, Hu Y, et al.Role of Fractalkine in promoting inflammation in sepsis-induced multiple organ dysfunction[J]. Infect Genet and Evol, 2020, 85: 104569. [5] van der Poll T, Shankar-Hari M, Wiersinga WJ. The immunology of sepsis[J]. Immunity, 2021, 54(11): 2450-2464. [6] Chaudhary K, Vaid A, Duffy Á, et al.Utilization of deep learning for subphenotype identification in sepsis-associated acute kidney injury[J]. Clin J Am Soc Nephrol, 2020, 15(11): 1557-1565. [7] Peters-Sengers H, Butler JM, Uhel F, et al.Source-specific host response and outcomes in critically ill patients with sepsis: a prospective cohort study[J]. Intensive Care Med, 2022, 48(1): 92-102. [8] Finotello F, Trajanoski Z.Quantifying tumor-infiltrating immune cells from transcriptomics data[J]. Cancer Immunol Immunother, 2018, 67(7): 1031-1040. [9] Katzman JL, Shaham U, Cloninger A, et al.DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network[J]. BMC Med Res Methodol, 2018, 18(1): 1-12. [10] Sperk M, Domselaar RV, Neogi U.Immune checkpoints as the immune system regulators and potential biomarkers in HIV-1 infection[J]. Int J Mol Sci, 2018, 19(7): 2000. [11] Letourneur D, Danlos FX, Marabelle A.Chemokine biology on immune checkpoint-targeted therapies[J]. Eur J Cancer, 2020, 137: 260-271. [12] Jiang W, Li X, Ding H, et al.PD-1 in Tregs predicts the survival in sepsis patients using sepsis-3 criteria: A prospective, two-stage study[J]. Int Immunopharmacol, 2020, 89(Pt A):107175. [13] Maiza H,Leca G,Mansur IG,et al.A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity[J]. J Exp Med,1993,178(3):1121-1126. [14] Inoue S, Bo L, Bian J, et al.Dose dependent effect of anti-CTLA-4 on survival in sepsis[J]. Shock, 2011, 36(1): 38-44. [15] Karbian N, Abutbul A, El-Amore R, et al.Apoptotic cell therapy for cytokine storm associated with acute severe sepsis[J]. Cell Death Dis, 2020, 11(7): 535. [16] Chousterman BG, Boissonnas A, Poupel L, et al.Ly6Chigh monocytes protect against kidney damage during sepsis via a CX3CR1-dependent adhesion mechanism[J]. J Am Soc Nephrol, 2016, 27(3): 792-803. [17] Hoogendijk AJ, Wiewel MA, van Vught LA, et al. Plasma fractalkine is a sustained marker of disease severity and outcome in sepsis patients[J]. Crit Care, 2015, 19: 412. |